- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06875700
Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients (SPORE)
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients is not yet established. This study will assess beliefs about the heritability of leiomyosarcoma (LMS) and other cancers, and attitudes toward germline testing among LMS patients.
Study Overview
Status
Conditions
Detailed Description
This is a descriptive study to explore attitudes toward genomics and interest in receiving personal genetic information among patients with leiomyosarcoma (LMS). The study aims to:
- Assess LMS patients' beliefs and attitudes about the heritability of LMS.
- Assess LMS patients' interest in genetic testing and their preferences for receiving information about genetic testing.
Prior studies of cancer patients have found strong interest in germline genetic testing to inform personal and familial cancer risk. However, germline genetic testing is not widely recommended for patients diagnosed with LMS, and little is known about patients' beliefs about the heritability of LMS or their interest in genetic testing. This study will use a survey to assess beliefs about the heritability of LMS, interest in genetic testing, and preferences for receiving information about genetic testing.
Participants will be identified by querying the Enterprise Data Warehouse (EDW) and the Huntsman Tumor Registry, recruiting in clinics at the Huntsman Cancer Institute, receiving referrals from providers outside the Huntsman Cancer Institute, and through LMS patient support and advocacy organizations.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Gregg Wood
- Phone Number: 801-646-4215
- Email: gregg.wood@hci.utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute at the University of Utah
-
Contact:
- Wendy K Kohlmann, MS
- Phone Number: 801-587-5556
- Email: wendy.kohlmann@hci.utah.edu
-
Principal Investigator:
- Wendy K Kohlmann, MS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population will be Patients with a confirmed or self reported diagnosis of LMS
Description
Inclusion
- Living
- Able to speak and read English or Spanish
- Mentally competent
- Age 18 or older
Exclusion
- <18 years
- Unable to read or write
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
Patients with leiomyosarcoma
Electronic questionnaire assessing beliefs about the heritability of LMS and interest in genetic testing |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beliefs about the heritability of Leiomyosarcoma
Time Frame: up to 1 day from study enrollment
|
This outcome will describe LMS patients' beliefs about the heritability of LMS as well as other cancers, diseases, and physical traits. A five point Likert scale is used to classify conditions from totally inherited to totally environmental. |
up to 1 day from study enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interest in germline genetic testing
Time Frame: up to 1 day from study enrollment
|
This outcome will report interest in genetic testing for cancer predisposition for themselves as well as for other people such as family members, children, and the general public. Likert scales will be used to assess general interest in genetics and genetic testing in general. Interest in genetic testing will also be assessed with questions about when in the lifespan testing should be offered and for which types of conditions. |
up to 1 day from study enrollment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Preferences for receiving information about genetic testing.
Time Frame: up to 1 day from study enrollment
|
This outcome will report the count of participants who self reported sources for genetic testing information as helpful. Participants will rank questions about sources of information from "1 Not helpful at all" to "6 Extremely helpful" on their baseline questionnaire. Participants who reported >5 on this scale are considered to have found the source for genetic testing information as helpful. This outcome will assess information presented in tables and graphs and information presented numerically . |
up to 1 day from study enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wendy Kohlmann, MS, Huntsman Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 165523
- 1P50CA272170-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Deidentified IDP will be shared with the University of Michigan Rogel Cancer Center for data analysis.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.